USA

Recurrent lupus nephritis less frequent after kidney transplant

Recurrent lupus nephritis less frequent after kidney transplant

Lupus nephritis is recurring less frequently among patients with end-stage renal disease who undergo kidney transplant, possibly due to improved immunosuppression, according to data presented by Debendra N. Pattanaik, MBBS, MD, of the University of Tennessee Health Science Center.Lupus nephritis is recurring less frequently among patients with end-stage renal disease who undergo kidney transplant, possibly due to improved immunosuppression, according to data presented by Debendra N. Pattanaik, MBBS, MD, of the University of Tennessee Health Science Center.

Lupus patients benefited from bioelectronic medicine treatment

Lupus patients benefited from bioelectronic medicine treatment

A pilot clinical trial showed that bioelectronic medicine treatment was effective in reducing fatigue and pain in lupus patients. The researchers also saw a decrease in arthritis. A pilot study is a small-scale preliminary study that examines the feasibility of an approach that researchers intend to use in a larger scale study.

Organs are not just bystanders, may be active participants in fighting autoimmune disease

Organs are not just bystanders, may be active participants in fighting autoimmune disease

Organs affected by autoimmune disease could be fighting back by "exhausting" immune cells that cause damage using methods similar to those used by cancer cells to escape detection, according to a study by researchers at the University of Pittsburgh School of Medicine published today in the Journal of Clinical Investigation.

Lupus affects more women than men. Why? New study explores

Lupus affects more women than men. Why? New study explores

Lupus affects nine times more women than men. Experts know that lupus erythematosus, SLE, or lupus affects many more women than men, but none of them can explain why. Now that University of Houston biomedical engineer Chandra Mohan has the funding, he has set out to determine why.

Prof. Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, has $2 million to solve the mystery.

Lilly to progress Olumiant into Phase 3 for lupus

Lilly to progress Olumiant into Phase 3 for lupus

The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).

According to the data, a statistically significant proportion of patients treated with 4mg of Olumiant (baricitinib) achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, thus meeting the primary endpoint of the trial.

Scientific and Technology Breakthroughs Show Promise for Lupus and Other Immunologic Diseases

Scientific and Technology Breakthroughs Show Promise for Lupus and Other Immunologic Diseases

The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson's lab at the University of California, San Francisco have developed an innovative way to engineer genes of the body's immune system to treat immunologic diseases like lupus, rheumatoid arthritis, cancer and HIV.